Back to today’s briefing

Story perspectives

Clairity's AI Tool Revolutionizes Breast Cancer Risk Prediction

6/3/2025

29 6

Summary

Story summary

Clairity, Inc. has secured FDA De Novo authorization for its groundbreaking AI platform, CLAIRITY BREAST, which predicts five-year breast cancer risk from standard mammograms. Set to launch in late 2025, this innovative tool promises to revolutionize early detection and personalized care, especially for women lacking family histories often neglected by traditional risk assessments.

1 of 1

Story summary

Clairity, Inc. has secured FDA De Novo authorization for its groundbreaking AI platform, CLAIRITY BREAST, which predicts five-year breast cancer risk from standard mammograms. Set to launch in late 2025, this innovative tool promises to revolutionize early detection and personalized care, especially for women lacking family histories often neglected by traditional risk assessments.